French court overturns €444m fine for Novartis, Roche

Two and a half years after France’s competition authority handed Novartis and Roche a hefty fine for allegedly using abusive practices to boost sales of their eye disease

NICE okays Roche liver cancer immunotherapy, Sanofi’s rare d...

Previously-untreated patients with hepatocellular carcinoma (HCC), a common form of liver cancer, will have an immunotherapy-based treatment option after NICE gave the nod to NHS funding of

Amgen's cancer biosimilars stay on US market as court battle...

Amgen has scored yet another home run in the US courts, this time seeing off a legal challenge from Genentech, which was trying to block it from launching two cut-price cancer biosimilars. 

Roche’s Tecentriq/Avastin combo gets liver cancer nod

The FDA has approved Roche’s combination of its Tecentriq and Avastin drugs in previously-untreated hepatocellular carcinoma (HCC) – the most common form of liver cancer.

MHRA says Avastin can be used for AMD despite Bayer, Novarti...

Roche raises 2019 outlook, shrugging off biosimilar threat